Issue 6 2022

20 Acquisition International - Issue 6 2022 Apr22002 Changing the World One Cell at a Time 2022’s Leading Innovators in Mammalian Cell Line Development – USA, AGC Biologics is one of the world’s most prestigious CDMOs, with projects including work on the Pfizer-BioNTech COVID-19 vaccine. The upcoming year will see AGC Biologics expand in order to remain on top of the rapidly growing demand for its services. ix years ago, CMC Biologics was acquired by the Japanese manufacturer of glass, chemicals, and high-tech materials, AGC Asahi Glass. The acquisition resulted in the 2018 amalgamation of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH (Heidelberg, Germany), and CMC Biologics, to create an international contract development and manufacturing organisation. Henceforth, AGC Biologics came to life, finding its home in Bothell, Washington, USA. AGC Biologics has since expanded its reach around the globe, setting up facilities in Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. As of 2022, the company is operating as an international leader in the development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. With over two decades of experience and over 175 customers supporting it, AGC Biologics is equipped to provide a unique insight into the industry and offer wholly bespoke services to its clients. It is this that inspires the company’s mission to work collaboratively with its clients in order to bring new biopharmaceuticals to the market. AGC Biologics strives to provide each client with a premium service through devoting itself to innovation and efficacy. Indeed, it is embedded in the company’s DNA to supply solutions that will guide its clients towards their goals and accelerate their project timelines through the utilisation of its cGMP-complaint facilities. Moreover, AGC Biologics’ strong partnerships with its clients enable the customers to openly communicate their budgetary requirements and needs throughout the process. This allows for more effective project management and enforces AGC Biologics’ devotion to delivering a reliable and compliant drug substance within the expected timeframe. Not only is AGC Biologics committed to its clients, but it is also motivated to be a sustainable business. The company boasts a stringent environmental policy that calls upon its team to take responsibility for their environmental impact – each employee is expected to adhere to the policy and report any concerns to AGC Biologics’ management team. Simply, AGC Biologics believes that it has an important obligation to all company stakeholders as well as the local communities in which it operates to ensure excellence in environmental performance. Consequently, this framework lays out ways in which the company can reduce its pollution, guides the company to use energy responsibly, and minimises waste. S The team backs this policy in its entirety as each member truly understands just how important sustainability is. Additionally, AGC Biologics’ workforce consists of some of the brightest individuals in the industry, boasting Kobe University, Vermont Law School, and Tokyo University alumni. For example, AGC Biologics’ CEO, Patricio Massera, possesses an MBA from UCEMA and a Biochemist degree from the University of Buenos Aires. Over 20 years of biologics experience informs his decisions and have, ultimately, led the company to great success. Busy is an understatement when describing the upcoming year – AGC Biologics will be working on multiple international and local projects. One of the company’s largest projects is centred around expansion. In the third quarter of 2022, AGC Biologics will begin working on the extension of its commercial-grade campus in Longmont, which will see the implementation of viral vector suspension technology and capacity for the development and manufacturing of gene therapies. The $30 million investment includes the addition of bioreactor sizes for product development and a complete range of commercial manufacturing capacities, meaning that the location will be able to fulfil and support the entire lifecycle of a project. Contact: Nick McDonald Company: AGC Biologics Web Address: https://www.agcbio.com/

RkJQdWJsaXNoZXIy MTQxNTg3MQ==